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Introduction:Wait times in cancer care continue to be an important
clinical, social, and political issue. This study examines wait times
along the care path from suspicious imaging study (Detection) to
adjuvant chemotherapy initiation (Chemotherapy) for patients with
early-stage non-small cell lung cancer (NSCLC) who undergo sur-
gical resection.
Methods: A retrospective chart review of patients diagnosed in
2005 with NSCLC who underwent curative-intent surgery in Nova
Scotia, Canada was conducted to abstract dates of care events
(Detection, Surgery Consultation, Surgery, Medical Oncology [MO]
Referral, MO Consultation and Chemotherapy) and patient charac-
teristics. Multifactorial regression methods were used to identify
statistically-significant cofactors associated with wait times at vari-
ous resolutions of care intervals (low, intermediate, high).
Results: A median wait time of 141 days elapsed between Detec-
tion-Chemotherapy; and a median 107 and 52 days elapsed between
Detection-Surgery and Surgery-Chemotherapy, respectively. A
number of demographic, clinical, epidemiological, and system re-
source dependant factors influenced wait times at different resolu-
tions, and were best detailed utilizing high resolution analysis. Wait
time between MO referral-MO Consultation was inversely related to
that experienced in the preceding interval of Surgery-MO Referral.
Conclusions: This study provides a first detailed examination of
wait times experienced by NSCLC patients undergoing curative-
intent surgery according to care interval definitions; demonstrates
the value of high care interval resolution analysis to detect bottle-
necks in access to care; and reports on the interdependence of
elapsed times between care events along the care path for cancer
patients.
Key Words: Non-small cell lung cancer, waiting times, elapsed
times, adjuvant chemotherapy.
(J Thorac Oncol. 2008;3: 865–870)
The assessment and management of wait times, or‘elapsed’ times, in cancer care continues to be an impor-
tant clinical, social, and political issue.1,2 Increasing efforts to
define benchmarks and monitor cancer wait times and imple-
ment wait time guarantees and other related initiatives are
currently underway in Canada.3–7 Studies examining wait
times, which attempt to identify delays and bottlenecks in
cancer care delivery, may provide a basis for evidence-based
strategies designed to improve cancer care and may aid in the
development of targeted solutions.
Recent studies in Nova Scotia,8–10 Canada, reporting
elapsed times along the care continuum for patients with
early-stage breast cancer have provided a framework that can
be used to explore cancer care timelines for other disease sites
such as non-small cell lung cancer (NSCLC). NSCLC repre-
sents approximately 80% of all lung cancer diagnoses and has
a 5-year overall survival rate of approximately 15%.11–13
Patients diagnosed with early-stage disease who undergo
surgical resection, however, represent a potentially-curable
population with a more favorable 5-year overall survival rate
of approximately 45%.14 For these patients, adjuvant chemo-
therapy for high-risk disease, has recently become a novel
standard of care based on the significant survival benefit
observed in a number of randomized controlled trials com-
paring adjuvant chemotherapy to observation alone.15–18 Thus
the spectrum of care for early-stage NSCLC now, extends
from disease presentation to adjuvant chemotherapy provi-
sion for selected cases.
To date, studies reporting wait times in lung cancer
management have focused on isolated elements of the care
spectrum such as; (i) time from symptom presentation to
diagnosis, and/or; (ii) time from diagnosis to definitive sur-
gical and/or radiation therapy.19–24 To our knowledge,
elapsed times from disease detection to initiation of adjuvant
chemotherapy for patients with NSCLC undergoing curative-
intent surgery have yet to be documented. The aims of this
study were to: (1) document elapsed times from disease detec-
tion to initiation of adjuvant systemic chemotherapy experienced
by patients with NSCLC undergoing curative-intent surgery
and; (2) examine the influence of demographic, clinical, epide-
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miologic, and system resource dependant factors upon elapsed
times, using three different care interval resolutions.
PATIENTS AND METHODS
A retrospective chart review was conducted to identify
the study cohort which included patients with stages I–III
NSCLC who underwent curative-intent surgery (Figure 1).
All patients were diagnosed in the year 2005, resided in
Nova Scotia, Canada and underwent surgical treatment at
either the QEII Health Sciences Centre (QEII HSC) in
Halifax or the Cape Breton Regional Hospital (CBRH) in
Sydney, Nova Scotia.
Patient demographics, disease, and treatment character-
istics and dates of care events were abstracted from radio-
logic, surgical, and pathology reports contained in patient
charts and from the Oncology Patient Information System, a
database maintained by the Nova Scotia Cancer Registry and
the regional cancer centers. Data quality in Oncology Patient
Information System is ensured through online system edits,
routine edits, and periodic charts audits.
Dates abstracted included: (i) disease detection (Detec-
tion), defined as the first abnormal imaging study prompting
surgical consultation (chest radiograph or computed tomog-
raphy scan), (ii) first surgical consultation (Surgery Consul-
tation), (iii) definitive curative-intent surgery (Surgery), (iv)
receipt of referral to medical oncology (MO) at one of the two
regional cancer centers (Nova Scotia Cancer Centre or Cape
Breton Cancer Centre) for consideration of adjuvant systemic
therapy (MO Referral), (v) first MO consultation and, (vi)
initiation of first cycle of adjuvant chemotherapy therapy
(Adjuvant Chemotherapy).
Elapsed times were examined at three levels of care
interval resolution or ‘definition’ (Figure 2): low (Detec-
tion—Adjuvant Chemotherapy); intermediate (Detection—
Surgery and Surgery—Adjuvant Chemotherapy); and high
(Detection—Surgery Consultation, Surgery Consultation—
Surgery, Surgery—MO Referral, MO Referral—MO Consul-
tation, and MO Consultation—Adjuvant Chemotherapy). AllFIGURE 1. Number of cases eligible for analyses.
FIGURE 2. Selected levels of resolution of care intervals for NSCLC care: (1) low-resolution (long composite interval embrac-
ing all events, Detection—Adjuvant Chemotherapy); (2) intermediate-resolution (midsize intervals embracing some, but not all
care events, Detection—Surgery, Surgery—Adjuvant Chemotherapy); (3) high-resolution (small intervals embracing single/
isolated care events, Detection—Surgery Consultation, Surgery Consultation—Surgery, Surgery—MO Referral, MO Refer-
ral—MO Consultation, MO Consultation—Adjuvant chemotherapy). MO, Medical Oncology.
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care intervals were calculated in calendar days, and only
those patients who experienced both events defining an in-
terval were included in the analysis of that interval.
A general linear model with a stepwise selection (p 
0.05) was used to identify the primary cofactors influencing
elapsed times at the three levels of care interval resolution.
Cofactors were initially entered into the stepwise selection
analysis only if their univariate probability of non-random
association was  0.3. The examined cofactors included:
patient sex (Sex), age at diagnosis (Age); marital status
(Marital status); smoking history (Smoking); lung cancer
subtype (Histopathology); pathologic stage of disease (Dis-
ease stage); the presence or absence of ischemic heart disease
or diabetes mellitus (Comorbidity); performance status based
on the Eastern Cooperative Oncology Group scale (Perfor-
mance status); health center where surgery occurred (Health
Centre); type of curative-intent surgery (Surgery type); pres-
ence or absence of post operative complications (PO compli-
cation); surgeon (Surgeon); medical oncologist (MO); dis-
tance of residence to a cancer center derived from address at
diagnosis (Distance to center); median household income in
the area of patient residence (MHI); mean level of education
in the area of patient residence (Education); and the wait/
elapsed time of the immediately preceding care event. Un-
derlying lung cancer histopathologies included were squa-
mous carcinoma, adenocarcinoma, and other (large cell
carcinoma and bronchio-alveolar carcinoma); mixed NSCLC-
small cell lung cancers were excluded. Aggregate census data
from 1996 and 2001 were used to compute the socio-eco-
nomic factors. Days were logarithmically transformed (ln
[days 1]) to better meet the assumption of data normality.25
Geometric mean wait times and their 95% confidence
intervals were estimated after adjusting for all cofactors that
significantly influenced wait times. Second-order (between-
cofactor) interactions were not studied due to the limited
statistical power of the study. Likewise, variations in MO
practices could not be accounted within multifactorial analy-
ses, due to the small number of entries (5) in each factor
level. The Tukey a posteriori test was used to identify
significant differences between covariate treatment levels.
Data quality control and analyses were performed using SAS
software (version 9.1)26 and R software27 (version 2.4.1).
RESULTS
Of the 540 patients diagnosed with NSCLC in 2005,
108 patients (20%) underwent curative-intent surgery, qual-
ifying for this study. Their characteristics are described in
Table 1. All 108 patients experienced timelines from disease
detection to surgical resection; 47 experienced timelines from
detection to MO referral for the consideration of adjuvant
chemotherapy; and 29 experienced timelines from detection
to initiation of adjuvant chemotherapy (Figure 1).
Elapsed times to care across all three resolutions of care
intervals are presented in Figure 3. A median of 141 days
elapsed between Detection—Adjuvant chemotherapy. At this
TABLE 1. Characteristics of Study Population
Demographics Disease Treatment
No. (%) No. (%) No. (%)
Sex Histopathology Health center
Female 47 (43.5) Adenocarcinoma 46 (42.6) QEII HSC 97 (89.8)
Male 61 (56.5) Squamous 35 (32.4) CBRH 11 (10.2)
Age at diagnosis Other 27 (25.0) Surgeon
60 29 (26.9) A 34 (31.5)
60 79 (73.1) Disease stage B 26 (24.1)
Marital status IA 42 (38.9) C 10 (9.3)
Married 75 (86.2) IB 25 (23.1) D 38 (35.2)
Single 12 (13.8) II 26 (24.1) Surgery type
Smoking history IIIa 15 (13.9) Lobectomy 72 (66.7)
Current smoker 36 (34.6) Pneumonectomy 16 (14.8)
Former smoker 55 (52.9) Margin status Wedge 20 (18.5)
Never 13 (12.5) Negative 99 (97.1) Postoperative complications
Education Positive 3 (2.9) No 69 (63.9)
Median 44 (40.7) Yes 39 (36.1)
Median 64 (59.3) Comorbidity Medical oncologist
Medium household income No 69 (67.0) A 7 (16.3)
Lowest ($40,000) 47 (43.5) Yes 34 (33.0) B 3 (7.0)
Highest ($40,000) 61 (56.5) C 2 (4.7)
Distance to center Performance status D 12 (27.9)
Near (32 km) 56 (51.9) 0–I 77 (71.3) E 5 (11.6)
Far (32 km) 52 (48.1) II–III 31 (28.7) F 7 (16.3)
G 7 (16.3)
a Two patients underwent curative-intent surgery with complete resection of stage IIIB NSCLC and were included in this study.
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low resolution care interval, the health center providing surgical
resection was the strongest predictor of elapsed time, with
timelines for patients treated at the QEII HSC being on average
approximately twice as long as those for patients treated at the
CBRH (QEII HSC versus CBRH: 165 versus 85 days, p 
0.001). Median household income also influenced timelines to
initiate adjuvant treatment, with patients living in areas of lower
MHI generally experiencing shorter timelines (p  0.014).
When timelines were examined at intermediate resolu-
tion of care intervals, a median of 107 days elapsed between
Detection—Surgery and a median of 52 days elapsed be-
tween Surgery—Adjuvant Chemotherapy. Shorter timelines
between Detection—Surgery were associated with former
smokers (former versus current versus never: 96 versus 121
versus 185 days, respectively, p  0.007), patients living in
areas of lower MHI (p  0.053), or having had surgery at the
CBRH (CBRH versus QEII HSC: 65 versus 120 days, re-
spectively, p  0.009). Timelines between Surgery—Adju-
vant Chemotherapy were weakly associated with patient age:
those aged 60 years and younger had a shorter timeline
compared with older patients (Age 60 versus 60: 50
versus 61 days, p  0.058). Overall timelines between De-
tection—Surgery were highly variable as 13% of patients (14
of 108 cases) had their disease monitored through serial
imaging, for at least 300 days, and up to a period of 1583
days, before undergoing surgery.
When timelines were examined at high resolution of
care intervals, a median of 45 days elapsed between Detec-
tion—Surgery Consultation, and a median of 52 days elapsed
between Surgery Consultation—Surgery. None of the evalu-
ated cofactors significantly influenced the former interval,
whereas the latter was associated with the health center
providing surgical resection (QEII HSC versus CBRH: 58
versus 27 days, p  0.003), MHI (shorter time with lower
MHI, p  0.017) and underlying histopathology (Squamous
versus Adenocarcinoma versus Other: 41 versus 58 versus 69
Detection MO Consultation
Surgery
Consultation Surgery MO Referral
Adjuvant 
Chemotherapy
141
(111-183)
[22]
1071
(73-141)
[102]
52
(32-78)
[107]
29
(17-52)
[43]
52
(43-70)
[26]
7
(6-12)
[23]
17
(12-26)
[43]
45
(22-72)
[107]
MHI p = 0.017
Shorter time with < income [107]
Distance to center p = 0.077
Shorter time with < distance [107]
Histopathology2 p = 0.032
Adenocarcinoma: 58ab(46 – 72) [46]
Squamous:           41a (31 – 53) [35]
Other:                    69b (51 – 94) [26]
Health center p = 0.003 
QEII HSC:  58 (50 – 68) [96]
CBRH:  27 (16 – 43) [11]
Education p = 0.127
≤ median:  50 (37 – 68) [44]
> median: 37 (29 – 48) [63]
Comorbidity p = 0.036
No:    27 (21 – 35) [32] 
Yes:  49 (31 – 77) [11]
Surgeon2 p = 0.008 
A:  39ab (26 – 58) [13]
B:  57b (36 – 91) [10]
C:  21a (12 – 37) [ 7]
D:  20a(13 – 31) [13]
Smoking2 p = 0.134
Current:  21ab (16 – 26) [12] 
Former:  15a (13 – 17) [27]
Never:    26b (17 – 38) [ 4]
Histopathology2 p = 0.154 
Adenocarcinoma: 16a (13 – 20) [17] 
Squamous:            15a (13 – 19) [16]
Other:                     21a (17 – 28) [10]
Surgery type2 p = 0.032
Lobectomy:           19b (16 – 22) [27]
Pneumonectomy: 13a ( 11 – 17) [14]
Wedge:                 25ab (14 – 45) [ 2]
Timeline Surgery—MO Referral
p = 0.002 
Shorter time with longer timeline 
between Surgery-MO Referral [43]
Marital status  p = 0.161
Married:   8 ( 6 – 12) [17]
Single:      5 ( 2 – 9) [ 6]
Sex p = 0.033
Female:  5 ( 3 – 7) [ 9]
Male:     10 ( 7 – 14) [14]
Performance status p = 0.041
0-I:     6 ( 4 – 9) [19]
II-III:  14 ( 7 – 28) [ 4]
PO complication p = 0.126
No:    9 ( 6 – 14) [13]
Yes:  5 ( 3 – 9) [10]
Smoking2 p = 0.007
Current:  121ab (97 – 152) [34] 
Former:    96a (80 – 115) [55]
Never:    185b (128 – 266) [13]
MHI p = 0.053
Shorter time with > income [102]
Age  p = 0.058
≤ 60:  50 (44 – 57) [15]
> 60:  61 (53 – 71) [11]
Education p = 0.192
≤ median:  60 (51 – 70) [10]
> median: 52 (46 – 58) [16]
Marital status  p = 0.187
Married:  133 (116 – 153) [16]
Single:    167 (129 – 215) [ 6]
MHI p = 0.014
Shorter time with < income [22]
Health center  p < 0.001
QEII HSC:  165 (145 – 187) [17]
CBRH:          85 ( 64 – 111) [ 5]
1 Timeline including all cases. Median time from Detection—Surgery was 102 days (quartiles 71, 132) when excluding cases who have experienced more than 300 days between disease detection and surgery due to 
disease monitoring. 
2 Statistically significant pairwise comparisons resulting from a posteriori Tukey tests are annotated with different subscripts. For example, former smokers experienced significantly shorter elapsed times between 
Detection—Surgery than did patients who had never smoked. Timelines for former vs current smokers did not differ significantly nor did timelines for current smokers vs those who had never smoked. 
Performance status p = 0.061
Shorter time with < PS [102]
Health center p = 0.009
QEII HSC:  120 (104 – 137) [92]
CBRH:          65 ( 42 – 99) [10]
Histopathology2 p = 0.159
Adenocarcinoma: 54a (47 – 63) [11]
Squamous:           49a (41 – 58) [ 8]
Other:                    63a (52 – 76) [ 7]
Health center p = 0.116
QEII HSC:  57 (51 – 64) [20]
CBRH:        47 (39 – 57) [ 6]
FIGURE 3. Wait times at three resolutions of care intervals: low (dotted), intermediate (dashed) and high (solid). Shown in
diamonds, is the median number of days (unadjusted for cofactors) with first and third quartiles. Below each interval are the
covariates retained in the final GLM model, with geometric mean number of days (adjusted for cofactors) and associated 95%
confidence intervals (in parenthesis). The sample size appears in square brackets. MO, Medical Oncology.
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days, p  0.032). Postoperatively, patients offered a MO
referral experienced the following timelines: 29 median days
between Surgery—MO Referral; 16 days between MO Re-
ferral—MO Consultation and; 7 days between MO Consul-
tation—Adjuvant Chemotherapy. Timelines between Sur-
gery—MO Referral were associated with the surgeon
requesting the MO Referral (Surgeon A versus B versus C
versus D: 39 versus 57 versus 21 versus 20 days, p  0.008),
and underlying patient comorbidities (presence versus ab-
sence of comorbidity: 49 days versus 27 days, p  0.036).
Timelines between MO Referral—MO Consultation were
significantly associated with surgery type (pneumonectomy
versus lobectomy: 13 versus 19 days, p  0.032), and
inversely related to the timelines experienced in the prior care
event of Surgery—MO Referral (p  0.002). Finally, MO
Consultation—adjuvant Chemotherapy elapsed times were
significantly shorter for females (females versus males: 5
versus 10 days, p 0.033) and those with better performance
status (0-I versus II-III: 6 versus 14 days, p  0.041).
INTERPRETATION
This study provides a snap shot of elapsed times along the
spectrum of cancer management for patients diagnosed with
early-stage NSCLC in 2005 and who underwent curative-intent
surgery in Nova Scotia, Canada. Timelines were influenced by a
number of cofactors that were patient-related (e.g., age, sex,
smoking history, and MHI), disease-related (e.g., histopathol-
ogy, performance status, and comorbidity), and treatment- or
system-related (e.g., surgery type, surgeon, and treatment cen-
ter). These cofactors and the magnitude of their influence varied
considerably with the definition of the care interval assessed,
illustrating the inherent complexity associated with wait time
analyses even within a seemingly uniform patient population.
Moreover, there was evidence that elapsed times along the care
path may be influenced by timelines experienced previously
along the care continuum. In this study, the time elapsed be-
tween MO Referral—MO Consultation was most significantly
(p  0.002) influenced by the time elapsed in the immediately
preceding care interval (Surgery—MO Referral): patients expe-
riencing long Surgery—MOReferral timeline received a consult
with a medical oncologist more rapidly. This inverse relation-
ship suggests that wait time to MO may not have been solely
disease-driven. It is possible that health care providers were
trying to compensate for system driven constraints (i.e., large
variation in the timing of referral to MO post surgery ranging
between 20 and 57 days) by prioritizing consultations for late
referrals in an attempt to provide chemotherapy within a 6–8
week timeframe after surgery, as mandated in the randomized
clinical trials demonstrating benefit of adjuvant chemotherapy
for NSCLC.15–18
System-related variables associated with wait times,
such as health center and surgeon, deserve special attention as
they could provide opportunities for intervention. In our
study, Surgery Consultation—Surgery wait times were longer
at the QEII HSC, a high volume hospital that provides
surgical treatment for nearly 90% of NSCLC patients, com-
pared with that at the CBRH (QEII HSC versus CBRH: 58
versus 27 days, p  0.003). This could reflect differences in
practice patterns and/or system-capacity between these two
centers; there was a significant shortage of both anesthesiol-
ogy and operating room staff and space at the QEII HSC over
the study period. As well, Surgery—MO Referral wait times
were associated with the surgeon requesting the MO Referral
(Surgeon A versus B versus C versus D: 39 versus 57 versus
21 versus 20 days, p  0.008). This could also reflect
differences in practice patterns among physicians and/or
differences in system-capacity at physician- and/or health
center-levels. Targeting these system-related variables, which
are potentially modifiable, could improve on the current wait
times, if desirable.
In the context of monitoring and evaluating wait times,
this study and our previous work in early breast cancer,
suggests that examining care time intervals may be most
informative when expressed at the highest possible resolu-
tion.8–10 For example, in this study, an average of 142 days
(median 141 days; quartiles 111, 183 days) elapsed between
disease detection and start of adjuvant chemotherapy treat-
ment. At this lowest resolution, timelines were strongly
associated with the health center providing the surgical re-
section; patients treated surgically at the CBRH initiated
chemotherapy 85 days post detection and those treated sur-
gically at the QEII HSC initiated chemotherapy 165 days post
detection. When examined at an intermediate resolution, the
influence of the health center was isolated to the Detection—
Surgery interval. At the highest resolution, the health center
influence was identified to be occurring in the Surgery Con-
sultation—Surgery interval. Examining timelines at high res-
olution therefore, as opposed to low or intermediate resolu-
tion, may help identify bottlenecks in care delivery, and
provide opportunities for intervention.
The continuum of care for early-stage cancers such as
NSCLC, breast, and colorectal cancers involves similar steps
from disease detection to adjuvant therapy. A uniform frame-
work to monitor wait times for cancer care across these disease
sites could, therefore, be helpful in furthering the understanding
of the dynamic processes influencing care delivery in cancer
care systems. However, direct comparisons of wait times among
these cancer sites, though plausible, are not recommended. At a
superficial level, the care path for these cancers, especially for
early-stage disease, may appear quite similar as it involves
undergoing curative-intent surgery after cancer detection fol-
lowed by adjuvant therapy for those with high-risk disease.
However, the underlying disease biology and management ap-
proaches are quite different. In this study, the median wait times
of 107 days between Detection—Surgery appeared considerable
if compared with timelines experienced by women diagnosed
with early-stage breast cancer who wait a median of approxi-
mately 36 days to surgery.8–10 Of note, however, the time
elapsed between Detection—Surgery for NSCLC was highly
variable, ranging from 0 to 1593 days, which appeared at least
partly driven by a subset of patients (13%) who underwent a
period of monitoring for a solitary pulmonary nodule before
surgical resection. This monitoring strategy may parallel ap-
proaches adopted in the management of some cancers such as
early stage prostate cancer but not others such as early stage
breast and colorectal cancer.
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This study has limitations. First, the number of cases
meeting the inclusion criteria was relatively small, reducing the
overall statistical power of the study and limiting the stability of
weak associations. Second, the retrospective nature of this study
did not allow a more comprehensive assessment of postopera-
tive complications and/or other comorbidities according to their
severity. Third, the date when the referral to surgeon was sent,
and the date when the surgeon decided a surgery was required,
were both unavailable. The former would have been required to
compute the timelines from Detection—Surgery Referral and
improve the resolution of the information examined. The latter
would have helped us distinguish between disease driven time-
lines and those reflective of system efficiency. As such, prospec-
tive monitoring of wait times in future studies should enable the
collection of these dates to address these limitations. Further, the
care interval between surgical consultation and surgery involves
other events that could have been examined at a higher resolu-
tion: diagnostic procedure (e.g., mediastinoscopy), preoperative
assessments (e.g., lung function tests), etc.
In summary, this study provides the first detailed ex-
amination of timelines experienced by cancer patients under-
going curative-intent surgery for NSCLC. The use of three
different care interval resolutions to report timelines supports
the value of high resolution intervals to effectively detect
access to care delays, and direct interventions. We suggest
that prospective reporting of care paths at high resolution
intervals, will aid in improving communication and transpar-
ency regarding wait times for cancer care. We also suggest
that an overall monitoring of wait times for different cancers
should take into account the unique underlying biology and
specific management approaches across seemingly similar yet
quite different cancer types. Finally, longer follow-up and
prospective collection of outcome data will be required to
elucidate the impact of prolonged wait times on survival.
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